Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Expansion Study of CX-5461 in Solid Tumours with BRCA2/PALB2 Mutation
NCT04890613Phase 1Recruiting
- Sponsor
- Senhwa Biosciences, Inc.
- Start
- Sep 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pidnarulex in solid tumor (4 cohorts), sponsored by Senhwa Biosciences, Inc. Primary endpoint: Recommended Phase 2 Dose. Started Sep 2021; status: recruiting.
02
Drugs
pidnarulex
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04890613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890613.